Pfizer Inc. announced that it has acquired a controlling interest in REDVAX GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. REDVAX GmbH is a preclinical stage company. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of cytomegalovirus (CMV) and a further undisclosed field. This transaction provides Pfizer Inc. access to a preclinical human CMV vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

Lenz & Staehelin advised Pfizer in this transaction. The Lenz & Staehelin team was led by Stephan Erni (Partner, Corporate / M&A) and included associates Thomas Spörri (Corporate / M&A) and Remo Decurtins (Employment).